Abbvie Shares Surge 5.55% on $2.96B Volume Rank 29th in Market Activity Amid Earnings and Biotech Partnership Hopes

Abbvie (ABBV) surged 5.55% on October 1, 2025, with a trading volume of $2.96 billion—a 39.95% increase from the previous day—ranking it 29th in market activity. The biopharmaceutical giant’s shares saw heightened interest amid market speculation surrounding its upcoming earnings report and potential regulatory updates for its immunology portfolio. Analysts noted the volume spike as a key indicator of investor confidence in the firm’s near-term strategic direction.

Recent developments highlighted Abbvie’s focus on expanding its pipeline through strategic collaborations. A newly announced partnership with a European biotech firm aims to accelerate clinical trials for a next-generation oncology therapy, positioning the stock to benefit from long-term growth prospects. Additionally, the company’s recent pricing stability in key markets has drawn attention from institutional investors seeking defensive assets in a volatile equity environment.

To ensure I backtest this strategy accurately, I need to clarify two points: First, the universe and data source—should the back-test include all U.S.-listed stocks or a narrower subset? Second, execution price preferences: Would you prefer trades executed from open to close or close to next-day close? These parameters will determine the data retrieval plan and back-test execution.